CA2216856C - Methodes de criblage d'agents therapeutiques a l'aide de nouvelles proteines modulatrices de l'apoptose - Google Patents

Methodes de criblage d'agents therapeutiques a l'aide de nouvelles proteines modulatrices de l'apoptose Download PDF

Info

Publication number
CA2216856C
CA2216856C CA002216856A CA2216856A CA2216856C CA 2216856 C CA2216856 C CA 2216856C CA 002216856 A CA002216856 A CA 002216856A CA 2216856 A CA2216856 A CA 2216856A CA 2216856 C CA2216856 C CA 2216856C
Authority
CA
Canada
Prior art keywords
bak
protein
proteins
viral
agents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA002216856A
Other languages
English (en)
Other versions
CA2216856A1 (fr
Inventor
Philip J. Barr
Michael C. Kiefer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Tanox Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tanox Inc filed Critical Tanox Inc
Publication of CA2216856A1 publication Critical patent/CA2216856A1/fr
Application granted granted Critical
Publication of CA2216856C publication Critical patent/CA2216856C/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002216856A 1995-04-20 1996-04-19 Methodes de criblage d'agents therapeutiques a l'aide de nouvelles proteines modulatrices de l'apoptose Expired - Lifetime CA2216856C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42652995A 1995-04-20 1995-04-20
US08/426,529 1995-04-20
PCT/US1996/005639 WO1996033416A1 (fr) 1995-04-20 1996-04-19 Methodes de criblage d'agents therapeutiques a l'aide de nouvelles proteines modulatrices de l'apoptose

Publications (2)

Publication Number Publication Date
CA2216856A1 CA2216856A1 (fr) 1996-10-24
CA2216856C true CA2216856C (fr) 2008-02-19

Family

ID=23691171

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002216856A Expired - Lifetime CA2216856C (fr) 1995-04-20 1996-04-19 Methodes de criblage d'agents therapeutiques a l'aide de nouvelles proteines modulatrices de l'apoptose

Country Status (5)

Country Link
EP (1) EP0821793A1 (fr)
JP (1) JP3615552B2 (fr)
AU (1) AU5568396A (fr)
CA (1) CA2216856C (fr)
WO (1) WO1996033416A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE315643T1 (de) * 1993-11-30 2006-02-15 Tanox Inc Cdn apoptosis modulierende proteine, sie kodierende dns und verfahren zu ihrer verwendung
US6441135B1 (en) 1997-03-20 2002-08-27 Tanox, Inc. Bak binding protein, DNA encoding the protein, and methods of use thereof
US6344330B1 (en) 1998-03-27 2002-02-05 The Regents Of The University Of California Pharmacophore recombination for the identification of small molecule drug lead compounds
EP1370678A4 (fr) * 2001-03-02 2005-09-07 Mds Proteomics Inc Methodes et reactifs de regulation de l'apoptose

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995005738A1 (fr) * 1993-08-20 1995-03-02 Massachusetts Institute Of Technology Agents anticancereux et apoptose
US5700638A (en) * 1993-08-26 1997-12-23 Washington University Cell death regulator
ATE315643T1 (de) * 1993-11-30 2006-02-15 Tanox Inc Cdn apoptosis modulierende proteine, sie kodierende dns und verfahren zu ihrer verwendung

Also Published As

Publication number Publication date
AU5568396A (en) 1996-11-07
JP3615552B2 (ja) 2005-02-02
JPH11504423A (ja) 1999-04-20
EP0821793A1 (fr) 1998-02-04
WO1996033416A1 (fr) 1996-10-24
CA2216856A1 (fr) 1996-10-24

Similar Documents

Publication Publication Date Title
JP4129055B2 (ja) 新規なアポトーシス調整タンパク質、そのタンパク質をコードするｄｎａおよびその使用方法
US20060127927A1 (en) Mammalian IAP gene family, primers, probes, and detection methods
US5919912A (en) Mammalian IAP antibodies and diagnostic kits
KR100536394B1 (ko) Fas/ap01수용체들의기능조절인자
WO2000015790A2 (fr) Genes induits par la leptine
CA2216856C (fr) Methodes de criblage d'agents therapeutiques a l'aide de nouvelles proteines modulatrices de l'apoptose
AU746135B2 (en) PARG, a GTPase activating protein which interacts with PTPL1
US9943567B2 (en) Method for treating arthritis using IK factor or nucleic acid encoding IK factor
US5998131A (en) Screening methods for the identification of compounds capable of abrogating BaK-BHRF-1 protein interactions
EP0830375A1 (fr) Inhibiteur humain du gene 1 de l'apoptose
EP1012262A1 (fr) Proteine humaine hflp
US20030073159A1 (en) Human inhibitor of apoptosis gene 1
US6489138B1 (en) Human ependymin
JPH11507825A (ja) Ｄｎアーゼ活性を有する蛋白質
AU719576B2 (en) Protein which binds ATP and nucleic acid and which possesses putative helicase and ATPase properties
WO1996023410A1 (fr) Enzymes 7, 8 et 9 de conjugaison d'ubiquitine
AU2004245959A1 (en) Methods for screening inhibitors of apoptosis
US7309783B2 (en) Mammalian early developmental regulator gene
JP2000116384A (ja) 新規遺伝子及びそれにコ―ドされる蛋白質ｐｇｔｈ
JP2000500962A (ja) Ｆｍｒ１関連蛋白質
WO1999021983A1 (fr) Gene humain de type atrophine 1
JPH1084971A (ja) 新規ストレス蛋白質
JP2002369685A (ja) アポトーシス遺伝子１のヒトインヒビター
JPH11206390A (ja) 新規な使用
JP2002262878A (ja) 転写制御剤

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20160419